Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations

References

• Giustini N, Bernthal NM, Bukata SV, Singh AS. Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature. Clin Sarcoma Res. 2018;8:14. doi:10.1186/s13569-018-0101-2
   PubMed Web of Science ®Google Scholar
• Staals EL, Ferrari S, Donati DM, Palmerini E. Diffuse-type tenosynovial giant cell tumour: current treatment concepts and future perspectives. Eur J Cancer. 2016;63:34–40. doi:10.1016/j.ejca.2016.04.022
   PubMed Web of Science ®Google Scholar
• Palmerini E, Longhi A, Donati DM, Staals EL. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy. Expert Rev Anticancer Ther. 2020;20(6):441–445. doi:10.1080/14737140.2020.1757441
   PubMed Web of Science ®Google Scholar
• Healey JH, Bernthal NM, van de Sande M. Management of tenosynovial giant cell tumor: a neoplastic and inflammatory disease. J Am Acad Orthop Surg Glob Res Rev. 2020;4(11):e20.00028. doi:10.5435/JAAOSGlobal-D-20-00028
   PubMedGoogle Scholar
• Baldi GG, Gronchi A, Stacchiotti S. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors. Expert Rev Clin Pharmacol. 2020;13(6):571–576. doi:10.1080/17512433.2020.1771179
   PubMed Web of Science ®Google Scholar
• de Saint Aubain Somerhausen N, van de Rijn M. Synovial giant cell tumours. In: Antonescu CRW, editor. WHO Classification of Tumours: Soft Tissue and Bone Tumours. 5th ed. International Agency for Research on Cancer; 2020:133–136.
   Google Scholar
• Bernthal NM, Spierenburg G, Healey JH, et al. The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study. Orphanet J Rare Dis. 2021;16(1):191. doi:10.1186/s13023-021-01820-6
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Wagner AJ, Tap WD, et al. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. Cancer. 2021;127(6):884–893. doi:10.1002/cncr.33312
   PubMed Web of Science ®Google Scholar
• West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A. 2006;103(3):690–695. doi:10.1073/pnas.0507321103
   PubMed Web of Science ®Google Scholar
• Vougiouklakis T, Shen G, Feng X, Hoda ST, Jour G. Molecular profiling of atypical tenosynovial giant cell tumors reveals novel non-CSF1 fusions. Cancers. 2019;12(1):100. doi:10.3390/cancers12010100
   PubMed Web of Science ®Google Scholar
• Benner B, Good L, Quiroga D, et al. Pexidartinib, a novel small molecule CSF-1R Inhibitor in use for tenosynovial giant cell tumor: a systematic review of pre-clinical and clinical development. Drug Des Devel Ther. 2020;14:1693–1704. doi:10.2147/dddt.S253232
   PubMed Web of Science ®Google Scholar
• Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394(10197):478–487. doi:10.1016/s0140-6736(19)30764-0
   PubMed Web of Science ®Google Scholar
• Mastboom MJL, Palmerini E, Verspoor FGM, et al. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. Lancet Oncol. 2019;20(6):877–886. doi:10.1016/s1470-2045(19)30100-7
   PubMed Web of Science ®Google Scholar
• Griffin AM, Ferguson PC, Catton CN, et al. Long-term outcome of the treatment of high-risk tenosynovial giant cell tumor/pigmented villonodular synovitis with radiotherapy and surgery. Cancer. 2012;118(19):4901–4909. doi:10.1002/cncr.26529
   PubMed Web of Science ®Google Scholar
• Mollon B, Lee A, Busse JW, et al. The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee: an individual patient meta-analysis. Bone Joint J. 2015;97-b(4):550. doi:10.1302/0301-620x.97b4.34907
   PubMed Web of Science ®Google Scholar
• Guo Q, Shi W, Jiao C, Xie X, Jiang D, Hu Y. Results and recurrence of pigmented villonodular synovitis of the ankle: does diffuse PVNS with extra-articular extension tend to recur more often? Knee Surg Sports Traumatol Arthrosc. 2018;26(10):3118–3123. doi:10.1007/s00167-017-4488-8
   PubMed Web of Science ®Google Scholar
• Xiang X, Jiang W, Qiu C, Xiao N, Liang J. Image-guided, intensity-modulated radiotherapy for the treatment of diffuse-type tenosynovial giant cell tumor of the knee: case report and review of the literature. Medicine. 2021;100(28):e26659. doi:10.1097/md.0000000000026659
   PubMed Web of Science ®Google Scholar
• Berger B, Ganswindt U, Bamberg M, Hehr T. External beam radiotherapy as postoperative treatment of diffuse pigmented villonodular synovitis. Int J Radiat Oncol Biol Phys. 2007;67(4):1130–1134. doi:10.1016/j.ijrobp.2006.10.016
   PubMed Web of Science ®Google Scholar
• Blanco CE, Leon HO, Guthrie TB. Combined partial arthroscopic synovectomy and radiation therapy for diffuse pigmented villonodular synovitis of the knee. Arthroscopy. 2001;17(5):527–531. doi:10.1053/jars.2001.24068
   PubMed Web of Science ®Google Scholar
• Horoschak M, Tran PT, Bachireddy P, et al. External beam radiation therapy enhances local control in pigmented villonodular synovitis. Int J Radiat Oncol Biol Phys. 2009;75(1):183–187. doi:10.1016/j.ijrobp.2008.10.058
   PubMed Web of Science ®Google Scholar
• Gortzak Y, Vitenberg M, Frenkel Rutenberg T, et al. Inconclusive benefit of adjuvant (90)yttrium hydroxyapatite to radiosynovectomy for diffuse-type tenosynovial giant-cell tumour of the knee. Bone Joint J. 2018;100-b(7):984–988. doi:10.1302/0301-620x.100b7.Bjj-2017-0867.R3
   PubMed Web of Science ®Google Scholar
• Dürr HR, Capellen CF, Klein A, et al. The effects of radiosynoviorthesis in pigmented villonodular synovitis of the knee. Arch Orthop Trauma Surg. 2019;139(5):623–627. doi:10.1007/s00402-018-3097-4
   PubMed Web of Science ®Google Scholar
• Ottaviani S, Ayral X, Dougados M, Gossec L. Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature. Semin Arthritis Rheum. 2011;40(6):539–546. doi:10.1016/j.semarthrit.2010.07.005
   PubMed Web of Science ®Google Scholar
• Park G, Kim YS, Kim JH, et al. Low-dose external beam radiotherapy as a postoperative treatment for patients with diffuse pigmented villonodular synovitis of the knee: 4 recurrences in 23 patients followed for mean 9 years. Acta Orthop. 2012;83(3):256–260. doi:10.3109/17453674.2012.678803
   PubMed Web of Science ®Google Scholar
• Lin C-S, Lan K-L, Wang L-W, et al. Treatment and outcome of tenosynovial giant cell tumor/pigmented villonodular synovitis patients receiving radiotherapy in Taiwan: a single-center experience. Ther Radiol Oncol. 2020;4:14. doi:10.21037/tro-20-41
   Google Scholar
• de Visser E, Veth RP, Pruszczynski M, Wobbes T, Van de Putte LB. Diffuse and localized pigmented villonodular synovitis: evaluation of treatment of 38 patients. Arch Orthop Trauma Surg. 1999;119(7–8):401–404. doi:10.1007/s004020050009
   PubMed Web of Science ®Google Scholar
• Cassier PA, Italiano A, Gomez-Roca CA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015;16(8):949–956. doi:10.1016/s1470-2045(15)00132-1
   PubMed Web of Science ®Google Scholar
• Bernthal NM, Ishmael CR, Burke ZDC. Management of pigmented villonodular synovitis (PVNS): an orthopedic surgeon’s perspective. Curr Oncol Rep. 2020;22(6):63. doi:10.1007/s11912-020-00926-7
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Cropet C, Chevreau C, et al. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2018;19(5):639–648. doi:10.1016/s1470-2045(18)30143-8
   PubMed Web of Science ®Google Scholar
• Cassier PA, Gelderblom H, Stacchiotti S, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer. 2012;118(6):1649–1655. doi:10.1002/cncr.26409
   PubMed Web of Science ®Google Scholar
• Smith BD, Kaufman MD, Wise SC, et al. Vimseltinib: a precision CSF1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages. Mol Cancer Ther. 2021;20(11):2098–2109. doi:10.1158/1535-7163.Mct-21-0361
   PubMed Web of Science ®Google Scholar
• Lewis JH, Gelderblom H, van de Sande M, et al. Pexidartinib long-term hepatic safety profile in patients with tenosynovial giant cell tumors. Oncologist. 2021;26(5):e863–e873. doi:10.1002/onco.13629
   PubMed Web of Science ®Google Scholar
• Tap WD, Wainberg ZA, Anthony SP, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373(5):428–437. doi:10.1056/NEJMoa1411366
   PubMed Web of Science ®Google Scholar
• Van De Sande M, Tap WD, Gelhorn HL, et al. Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. Acta Orthop. 2021;92(4):493–499. doi:10.1080/17453674.2021.1922161
   PubMed Web of Science ®Google Scholar
• Speck RM, Ye X, Bernthal NM, Gelhorn HL. Psychometric properties of a custom patient-reported outcomes measurement information system (PROMIS) physical function short form and worst stiffness numeric rating scale in tenosynovial giant cell tumors. J Patient Rep Outcomes. 2020;4(1):61. doi:10.1186/s41687-020-00217-6
   PubMedGoogle Scholar
• Turalio. Prescribing Information. Daiichi Sankyo, Inc; 2019.
   Google Scholar
• European Medicines Agency. Turalio. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/turalio. Accessed September 15, 2021.
   Google Scholar
• Smith CC, Levis MJ, Frankfurt O, et al. A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. Blood Adv. 2020;4(8):1711–1721. doi:10.1182/bloodadvances.2020001449
   PubMed Web of Science ®Google Scholar
• Lee JH, Chen TW, Hsu CH, et al. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Invest New Drugs. 2020;38(1):99–110. doi:10.1007/s10637-019-00745-z
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Approved risk evaluation and mitigation strategies (REMS). Available from: https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=389. Accessed September 15, 2021.
   Google Scholar
• Monestime S, Lazaridis D. Pexidartinib (TURALIO™): the first FDA-indicated systemic treatment for tenosynovial giant cell tumor. Drugs R D. 2020;20(3):189–195. doi:10.1007/s40268-020-00314-3
   PubMed Web of Science ®Google Scholar
• Wang XF, Wang YJ, Li TY, et al. Colony-stimulating factor 1 receptor inhibition prevents against lipopolysaccharide -induced osteoporosis by inhibiting osteoclast formation. Biomed Pharmacother. 2019;115:108916. doi:10.1016/j.biopha.2019.108916
   PubMed Web of Science ®Google Scholar
• Denny WA, Flanagan JU. Small-molecule CSF1R kinase inhibitors; review of patents 2015-present. Expert Opin Ther Pat. 2021;31(2):107–117. doi:10.1080/13543776.2021.1839414
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Yakoub MA, Chandler A, et al. CSF1/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment. Mol Cancer Ther. 2021;20(8):1388–1399. doi:10.1158/1535-7163.Mct-20-0591
   PubMed Web of Science ®Google Scholar
• Smeester BA, Slipek NJ, Pomeroy EJ, et al. PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma. Bone. 2020;136:115353. doi:10.1016/j.bone.2020.115353
   PubMed Web of Science ®Google Scholar
• Alhudaithi SS, Almuqbil RM, Zhang H, et al. Local targeting of lung-tumor-associated macrophages with pulmonary delivery of a CSF-1R inhibitor for the treatment of breast cancer lung metastases. Mol Pharm. 2020;17(12):4691–4703. doi:10.1021/acs.molpharmaceut.0c00983
   PubMed Web of Science ®Google Scholar
• Zhang H, Almuqbil RM, Alhudaithi SS, Sunbul FS, da Rocha SRP. Pulmonary administration of a CSF-1R inhibitor alters the balance of tumor-associated macrophages and supports first-line chemotherapy in a lung cancer model. Int J Pharm. 2021;598:120350. doi:10.1016/j.ijpharm.2021.120350
   PubMed Web of Science ®Google Scholar
• Pang L, Pei Y, Uzunalli G, Hyun H, Lyle LT, Yeo Y. Surface modification of polymeric nanoparticles with M2pep peptide for drug delivery to tumor-associated macrophages. Pharm Res. 2019;36(4):65. doi:10.1007/s11095-019-2596-5
   PubMed Web of Science ®Google Scholar
• Manji GA, Van Tine BA, Lee SM, et al. A phase I study of the combination of pexidartinib and sirolimus to target tumor-associated macrophages in unresectable sarcoma and malignant peripheral nerve sheath tumors. Clin Cancer Res. 2021;27(20):5519–5527. doi:10.1158/1078-0432.Ccr-21-1779
   PubMed Web of Science ®Google Scholar